Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $20 to $17.
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $20 to $17.